Measurement · not graded
Grip Strength Dynamometer
What the evidence looks at: test-retest reliability and agreement between dynamometers under a standardized protocol.
How this letter has changedLatest: September 2026 · First graded.
Same gap as DEXA: a published page with no record. The record carries no letter. It describes the instrument only, and says plainly that grip strength as a prognostic marker belongs with the biomarkers A measurable sign in the body, such as a blood test value, used to track a condition or the effect of a treatment. and that isometric handgrip training is a separate graded therapy, so a reading from this device says nothing about whether squeezing a handgrip treats anything. Cited: Roberts et al. (Age Ageing, 2011; PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 21624928); Dos Santos et al. (Hand Ther, 2026; PMID 40626051).PMID 21624928 PMID 40626051
Every change to a letter on this site is dated and published. The full evidence log →
Diagnostic device · Functional fitness
Grip strength is one of the most replicated The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away. independent predictors of all-cause mortality, cardiovascular disease, stroke, and cognitive decline in large human cohort studies An observational study that follows a group of people over time and compares what happens to them. including the UK Biobank (n=502,000). A hand dynamometer costs $30 to $50 and measures this biomarker directly in 30 seconds. It is the most cost-effective longevity diagnostic available and one of the few biomarkers where the test itself is also the training tool.
Grip strength is graded on the strength and consistency of its predictive evidence, not on an intervention effect. Two large prospective cohorts (PURE, n=139,691; UK Biobank, n≈502,000) independently link lower grip strength to higher all-cause and cardiovascular mortality. Because the mortality evidence is observational Research that watches what people already do rather than assigning a treatment. It can show that two things travel together, not that one causes the other. rather than randomized, the ceiling is Grade B under Rule 05, the same rule that caps infrared sauna at B.
The measurement is only useful if something changes it. Resistance training's Grade A rests on one-repetition maximum and muscle size, not on grip: in a meta-analysis A study that pools the numbers from several trials into one combined estimate. of randomized trials in adults 75 and over, handgrip strength did not change significantly with resistance training (Grgic 2020, PMID 32740889). A flat grip reading is therefore not evidence that the training has failed.
| Validated devices | Jamar Plus+ Digital Hand Dynamometer (clinical gold standard, $150). Camry EH101 ($30-40, validated in multiple studies). CAMRY Digital Hand Dynamometer. Most squeeze-type dynamometers read within 5% of Jamar. |
| Protocol | Dominant hand, arm at side, elbow slightly bent (20-30 degrees). Three maximal squeezes, 30 seconds rest between each. The measure is the best of three attempts. The same is repeated on the non-dominant hand. Standardize testing position across measurements. |
| Reference values (men) | Age 20-29: 46-56 kg. Age 40-49: 42-52 kg. Age 60-69: 35-45 kg. The EWGSOP2 consensus cut-point for low grip strength in men is 27 kg (PMID 30312372); cut-points vary by population and measurement protocol. |
| Reference values (women) | Age 20-29: 26-33 kg. Age 40-49: 24-32 kg. Age 60-69: 20-28 kg. The EWGSOP2 consensus cut-point for low grip strength in women is 16 kg (PMID 30312372); cut-points vary by population and measurement protocol. |
| Cost | $30 to $150 depending on model. Jamar Plus+ is the clinical reference. Camry EH101 is the best validated budget option. |
| Frequency | At every clinical encounter or quarterly self-assessment. |
Best of three squeezes dominant hand, kg. Compare to age and sex reference values. The trend over time matters more than any single reading. EWGSOP2 defines low grip strength as under 27 kg in men and under 16 kg in women (PMID 30312372). A reading below the cut-point is one of the criteria used in sarcopenia Age-related loss of muscle mass and strength. case-finding, not a diagnosis on its own, and cut-points differ between consensus groups and populations.
Prospective cohort of 139,691 adults across 17 countries. Each 5 kg decrease in grip strength was associated with a 17 percent increase in cardiovascular mortality, 17 percent increase in non-cardiovascular mortality, 9 percent increase in stroke, and 7 percent increase in myocardial infarction. Grip strength was a stronger predictor of cardiovascular mortality than systolic blood pressure in this study.
Analysis of roughly 500,000 UK Biobank participants. Low grip strength was independently associated with increased all-cause mortality, cardiovascular disease, respiratory disease, and cancer mortality after adjusting for age, sex, BMI, socioeconomic status, and physical activity. This is the largest single-cohort dataset linking grip strength to hard outcomes.
The EWGSOP2 sarcopenia consensus uses low grip strength as the primary diagnostic criterion for sarcopenia, preceding the assessment of muscle mass. Low grip strength below the reference thresholds is the first step in the sarcopenia diagnostic algorithm.
No safety concerns for standard grip strength testing in healthy adults. People with recent hand surgery, severe arthritis, or carpal tunnel syndrome are tested under clinical guidance. An acute hand or wrist injury invalidates the test.
No direct drug interactions with the measurement. Corticosteroids, statins at high doses, and medications causing myopathy can reduce grip strength over time, which is part of what a trend reflects.
Grip strength is the most accessible and cost-effective longevity biomarker on this platform. A $35 dynamometer and a 30-second test gives you an independent mortality predictor that updates with your training. The cohort literature treats grip strength as a tracked measure rather than a single reading, repeat testing at a fixed interval is what turns a number into a trend. What interval fits your situation is a conversation for you and your clinician.
Educational use only · Not medical advice · Starting, stopping or changing any supplement or medication is a decision for your physician
EBL does not verify the regulatory status of any device. Many consumer wellness devices are not FDA-cleared The FDA found a device substantially equivalent to one already on the market. Clearance is not approval and does not require trials showing benefit., and FDA clearance, where it exists, applies only to specific indications. The grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Using any device for a health purpose is a decision for your physician.
Primary evidenceTwo papers, each linked to its PubMed record.
Roberts and colleagues (Age and Ageing, 2011; PMID 21624928): review of how grip strength is measured across clinical and epidemiological studies, proposing one standardized protocol, since posture, elbow angle and instructions all move the number. Test-retest reliability and concurrent validity of three dynamometers, Jamar, Jamar Plus+ and Biodex, in healthy young adults (Hand Therapy, 2026; PMID 40626051). Both are measurement studies, not outcome trials.
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →